Drugmaker Accuses FDA Of ‘Arbitrarily And Capriciously’ Approving A Rival’s Treatment That’s Priced Significantly Lower

There's been an unusual and heated war being waged between Catalyst Pharmaceuticals and small, family-run Jacobus Pharmaceutical over their rare drug. The battle is being closely watched to see if incentives for developing such drugs may be jeopardized. Other pharmaceutical news focuses on GSK's investment in CRISPR, privacy and drug importation.

from Kaiser Health News http://bit.ly/2MP4jQk